Zobrazeno 1 - 10
of 382
pro vyhledávání: '"Lyudmila Bazhenova"'
Autor:
Santiago Viteri, Anna Minchom, Lyudmila Bazhenova, Sai‐Hong Ignatius Ou, Joshua M. Bauml, Scott A. Shell, Michael Schaffer, Junchen Gu, Jennifer B. Rose, Joshua C. Curtin, Parthiv Mahadevia, Nicolas Girard
Publikováno v:
Molecular Oncology, Vol 17, Iss 2, Pp 230-237 (2023)
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) account for ≤ 12% of all EGFR‐mutant nonsmall cell lung cancers. We analysed real‐world datasets to determine the frequency of ex20ins variants, and the ability of po
Externí odkaz:
https://doaj.org/article/c4da93c6b1ad420a85fa00e6dd68825d
Autor:
Benjamin Solomon, Ana Callejo, Jair Bar, Guy Berchem, Lyudmila Bazhenova, Pierre Saintigny, Fanny Wunder, Jacques Raynaud, Nicolas Girard, J. Jack Lee, Raed Sulaiman, Bruce Prouse, Catherine Bresson, Hila Ventura, Shai Magidi, Eitan Rubin, Brandon Young, Amir Onn, Brian Leyland‐Jones, Richard L. Schilsky, Vladimir Lazar, Enriqueta Felip, Razelle Kurzrock
Publikováno v:
Cancer Medicine, Vol 11, Iss 14, Pp 2790-2800 (2022)
Abstract Background The Worldwide Innovative Network (WIN) Consortium has developed the Simplified Interventional Mapping System (SIMS) to better define the cancer molecular milieu based on genomics/transcriptomics from tumor and analogous normal tis
Externí odkaz:
https://doaj.org/article/9a1795592c8e42cab3df58cfe6f8ac80
Autor:
Scott N. Gettinger, MD, Rudolf M. Huber, MD, PhD, Dong-Wan Kim, MD, PhD, Lyudmila Bazhenova, MD, Karin Holmskov Hansen, MD, Marcello Tiseo, MD, Corey J. Langer, MD, FACP, Luis G. Paz-Ares Rodríguez, MD, PhD, Howard L. West, MD, Karen L. Reckamp, MD, MS, Glen J. Weiss, MD, Egbert F. Smit, MD, PhD, Maximilian J. Hochmair, MD, Sang-We Kim, MD, PhD, Myung-Ju Ahn, MD, PhD, Edward S. Kim, MD, FACP, Harry J.M. Groen, MD, PhD, Joanna Pye, MS, Yuyin Liu, PhD, Pingkuan Zhang, MD, Florin Vranceanu, MD, PhD, D. Ross Camidge, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100385- (2022)
Introduction: We report brigatinib long-term efficacy and safety from phase 1/2 and phase 2 (ALTA) trials in ALK–rearrangement positive (ALK+) NSCLC. Methods: The phase 1/2 study evaluated brigatinib 30 to 300 mg/d in patients with advanced maligna
Externí odkaz:
https://doaj.org/article/78d40f5a880944a8b24323de142222e5
Publikováno v:
Cancer Treatment and Research Communications, Vol 33, Iss , Pp 100637- (2022)
Background: Treatment for recurrent or advanced/metastatic non-small cell lung cancer (aNSCLC) has advanced in the past 5 years with immunotherapy (IO). This study sought to describe first-line (1L) aNSCLC treatment patterns and clinical outcomes. Me
Externí odkaz:
https://doaj.org/article/144da45d10294ccb964be9bf646d34d1
Autor:
John Bridgewater, Xiaolong Jiao, Mounika Parimi, Clare Flach, Jeran Stratford, Atanas Kamburov, Arndt A. Schmitz, Jihong Zong, John A. Reeves, Karen Keating, Amanda Bruno, Marc Fellous, Mariana Buongermino Pereira, Lyudmila Bazhenova
Publikováno v:
Cancer Treatment and Research Communications, Vol 33, Iss , Pp 100623- (2022)
Introduction: Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are oncogenic drivers in various tumor types. Limited data exist on the overall survival (OS) of patients with tumors with NTRK gene fusions and on the co-occurrence of NTRK fusi
Externí odkaz:
https://doaj.org/article/9812c0175f7c49efba2bd73e1fd443b6
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/36f7cc63a8204217b15eec9590b79f5c
Autor:
Stephanie N. Shishido, Anders Carlsson, Jorge Nieva, Kelly Bethel, James B. Hicks, Lyudmila Bazhenova, Peter Kuhn
Publikováno v:
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-14 (2019)
Abstract Background Monitoring circulating tumor cells (CTC) has been shown to be prognostic in most solid malignancies. There is no CTC assay in clinical use for lung cancer therapy monitoring due to inconclusive clinical utility data. Limited data
Externí odkaz:
https://doaj.org/article/52f466d6503b4c999208b4245b29f262
Autor:
Jun Zhang, Melissa Johnson, Minal Barve, Lyudmila Bazhenova, Marybeth McCarthy, Rowena Schwartz, Elise Horvath-Walsh, Karen Velastegui, Chunlin Qian, Alexander Spira
Publikováno v:
The oncologist, vol 28, iss 4
Adagrasib (MRTX849) is a KRASG12C inhibitor with favorable properties, including long half-life (23 h), dose-dependent pharmacokinetics, and central nervous system (CNS) penetration. As of September 1, 2022, a total of 853 patients with KRASG12C-muta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82800b3a109243dd45ac2454e0b844f7
https://doi.org/10.1093/oncolo/oyad051
https://doi.org/10.1093/oncolo/oyad051
Autor:
James Chih-Hsin Yang, MD, PhD, Karen L. Reckamp, MD, Young-Chul Kim, MD, PhD, Silvia Novello, MD, PhD, Egbert F. Smit, MD, PhD, Jong-Seok Lee, MD, PhD, Wu-Chou Su, MD, Wallace L. Akerley, MD, Collin M. Blakely, MD, PhD, Harry J.M. Groen, MD, PhD, Lyudmila Bazhenova, MD, Enric Carcereny Costa, MD, Rita Chiari, MD, PhD, Te-Chun Hsia, MD, PhD, Tony Golsorkhi, MD, Darrin Despain, MStat, Danny Shih, BA, Sanjay Popat, BSc, MBBS, FRCP, PhD, Heather Wakelee, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 2, Pp 100114- (2021)
Introduction: The TIGER-3 (NCT02322281) study was initiated to compare the efficacy and safety of rociletinib, a third-generation EGFR tyrosine kinase inhibitor (TKI) that targets EGFR T790M and common EGFR-activating mutations, versus chemotherapy i
Externí odkaz:
https://doaj.org/article/3960fcdf0ad54bcf8d21572f501bc5e5
Autor:
Joseph M Unger, Lu Qian, Mary W Redman, Susan S Tavernier, Lori Minasian, Ellen V Sigal, Vassiliki A Papadimitrakopoulou, Michael Leblanc, Charles S Cleeland, Samuel A Dzingle, Thomas J Summers, Herta Chao, Sheshadri Madhusudhana, Liza Villaruz, Jeffrey Crawford, Jhanelle E Gray, Karen L Kelly, David R Gandara, Lyudmila Bazhenova, Roy S Herbst, Scott N Gettinger, Carol M Moinpour
Publikováno v:
JNCI: Journal of the National Cancer Institute. 115:437-446
Background An important issue for patients with cancer treated with novel therapeutics is how they weigh the effects of treatment on survival and quality of life (QOL). We compared QOL in patients enrolled to SWOG S1400I, a substudy of the LungMAP bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1976563759de6e6c88f60ed5bcd02a8a
https://doi.org/10.1093/jnci/djad003
https://doi.org/10.1093/jnci/djad003